<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552303</url>
  </required_header>
  <id_info>
    <org_study_id>817800</org_study_id>
    <nct_id>NCT02552303</nct_id>
  </id_info>
  <brief_title>The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia</brief_title>
  <official_title>The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceutical Industries, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of Armodafinil, CBT-I, or the combination&#xD;
      of the two on the sleep continuity of persons suffering from sleep disordered breathing and&#xD;
      their adherence to CBT-I and Continuous Positive Airway Pressure (CPAP). Adults diagnosed&#xD;
      with obstructive sleep apnea and who meet additional research and diagnostic criteria for&#xD;
      insomnia will be recruited. Participants will submit daily sleep diaries and supplemental&#xD;
      questionnaires as measures of study progress.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Insomnia and sleep disordered breathing are the most common sleep disorders and they tend to&#xD;
      be highly comorbid. When they co-occur, not only is there an increase in cumulative&#xD;
      morbidity, but it is likely that these two diseases interact to: promote overall greater&#xD;
      illness severity; reduce treatment adherence; and diminish treatment efficacy. The results&#xD;
      from the proposed project will provide valuable information on how co-treatment for these two&#xD;
      disorders can promote improved sleep quantity, enhanced sleep quality, better compliance with&#xD;
      Positive Airway Pressure (PAP) therapy, and better daytime functioning.&#xD;
&#xD;
      Background:&#xD;
&#xD;
      There is now substantial evidence that Cognitive Behavioral Therapy for Insomnia (CBT-I) is&#xD;
      efficacious for Primary Insomnia (PI), that it is as potent as sedative hypnotic treatment,&#xD;
      and better sustained over time. Further, there is now increasing evidence that CBT-I can be&#xD;
      applied to insomnias that are co-morbid with medical and psychiatric disorders, and with&#xD;
      equal efficacy. The evidence for an expanded indication, to date, has been for insomnia&#xD;
      comorbid with depression, chronic pain, and cancer. Interestingly, there are very few studies&#xD;
      on the efficacy of CBT-I in insomnia comorbid with other intrinsic sleep disorders, including&#xD;
      in patients with Sleep Disordered Breathing (SDB). This is surprising given that insomnia&#xD;
      frequently occurs comorbidly with SDB. It is estimated that 40-60% of patients with SDB also&#xD;
      suffer from insomnia. The lack of data regarding the applicability of CBT-I to insomnia&#xD;
      co-morbid with SDB is likely due to the concern that CBT-I will be difficult to tolerate in&#xD;
      patients with insomnia co-morbid with SDB given the treatment's tendency to produce acute&#xD;
      increases in fatigue, sleepiness, and transient reductions in attention and performance.&#xD;
      Accordingly, the investigators of this study propose to conduct a randomized, controlled&#xD;
      trial on the effects of Armodafinil alone and in combination with CBT-I in patients with&#xD;
      Insomnia comorbid with SDB.&#xD;
&#xD;
      Note: The choice to evaluate Armodafinil as both a monotherapy and an adjuvant therapy to&#xD;
      CBT-I for insomnia has a firm conceptual basis and is supported by preliminary data from our&#xD;
      group. The choice to evaluate Armodafinil in patients with insomnia co-morbid with SDB is&#xD;
      further supported by the existing indication for sleepiness in patients with SDB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change in Sleep Continuity From Baseline to Follow-up, as Measured by the Insomnia Severity Index (ISI).</measure>
    <time_frame>ISI is measured once at baseline and once at follow-up (8-10 weeks apart)</time_frame>
    <description>This outcome measure is based on changes in sleep continuity, as assessed by the Insomnia Severity Index (ISI), which is administered once at baseline and once at follow-up. The ISI (Morin, 1993) was used to assess perceived sleep difficulties or current insomnia symptom severity (i.e., past two weeks). The ISI is a 7-item, self-report instrument with good reliability and validity, and positively correlated with clinician-rated insomnia diagnoses (Bastien, Vallières, &amp; Morin, 2001). Total scores on the full 7-item scale range from 0 - 28 with higher values representing greater sleep continuity disturbance or insomnia severity.&#xD;
The four different treatment groups will be compared for differences.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Dropped Out</measure>
    <time_frame>up to 8 weeks of active study</time_frame>
    <description>Drop-out rates will be calculated by the number of protocol weeks the subject completed before withdrawing from the study. Drop out rates for subjects taking active v. placebo study medication were compared.&#xD;
Withdrawal indicates subjects who were either lost-to-follow-up (LTFU), chose to withdraw (self-withdrawn), were withdrawn by the study's PI (withdrawn by the investigator).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>CBT for Insomnia (CBTI) + Armodafinil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CBT-I with Armodafinil (active medication)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBTI + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cognitive Behavioral Therapy for Insomnia with Placebo medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Armodafinil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medication (armodafinil) only, without CBTI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo only, without CBTI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy for Insomnia</intervention_name>
    <description>Cognitive Behavioral Therapy for Insomnia.</description>
    <arm_group_label>CBT for Insomnia (CBTI) + Armodafinil</arm_group_label>
    <arm_group_label>CBTI + Placebo</arm_group_label>
    <other_name>CBT-I</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <description>Active medication</description>
    <arm_group_label>Armodafinil</arm_group_label>
    <arm_group_label>CBT for Insomnia (CBTI) + Armodafinil</arm_group_label>
    <other_name>NuVigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for Nuvigil (armodafinil)</description>
    <arm_group_label>CBTI + Placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  eligible subjects must have begun their CPAP treatment within the last 3 months&#xD;
&#xD;
          -  current ESS (Sleepiness) Scores between 5-19&#xD;
&#xD;
          -  no history of upper airway surgery (e.g. UPPP)&#xD;
&#xD;
          -  able to understand written and spoken English&#xD;
&#xD;
          -  able to swallow medication&#xD;
&#xD;
          -  preferred sleep phase between 9:00 pm and 9:00 am&#xD;
&#xD;
          -  willing to discontinue any sleep medications/over-the-counters(OTCs)/Herbals for&#xD;
             insomnia for the 11-week study period.&#xD;
&#xD;
          -  female participants must not be pregnant or breastfeeding and must agree to use two&#xD;
             forms of birth control during the study period, as Armodafinil may interfere with&#xD;
             hormonal birth control.&#xD;
&#xD;
          -  all participants will be asked to postpone any additional or alternate treatments for&#xD;
             their Obstructive Sleep Apnea (OSA) until after the completion of their participation&#xD;
             in this research study.&#xD;
&#xD;
          -  for other elective procedures, prospective participants are recommended to either&#xD;
             postpone the procedure until after completion of their participation in this study, or&#xD;
             alternatively to start the study after completion of the elective procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CPAP usage exceeding three months prior to pre-screening&#xD;
&#xD;
          -  suicide attempts within the last five years&#xD;
&#xD;
          -  unstable medical or psychiatric illness&#xD;
&#xD;
          -  cardiac abnormalities, liver, or kidney diseases&#xD;
&#xD;
          -  sleep disorders other than insomnia or SDB&#xD;
&#xD;
          -  evidence of active illicit substance use or fitting criteria for alcohol abuse or&#xD;
             dependence&#xD;
&#xD;
          -  use of central nervous system (CNS) active medications, antidepressants and hypnotics&#xD;
             prescribed as sleep-aids (these medications are permitted if prescribed for mediation&#xD;
             of symptoms other than sleep and the patient has been on a stable dosage for a minimum&#xD;
             of one month, with no anticipation of altering their dosage during the study period.)&#xD;
&#xD;
          -  inadequate language comprehension&#xD;
&#xD;
          -  pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael L Perlis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <results_first_submitted>December 21, 2016</results_first_submitted>
  <results_first_submitted_qc>June 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2017</results_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CBT for Insomnia (CBTI) + Armodafinil</title>
          <description>CBT-I with Armodafinil (active medication)&#xD;
Cognitive Behavioral Therapy for Insomnia: Cognitive Behavioral Therapy for Insomnia.&#xD;
Armodafinil: Active medication</description>
        </group>
        <group group_id="P2">
          <title>CBTI + Placebo</title>
          <description>Cognitive Behavioral Therapy for Insomnia with Placebo medication&#xD;
Cognitive Behavioral Therapy for Insomnia: Cognitive Behavioral Therapy for Insomnia.&#xD;
Placebo: Placebo for Nuvigil (armodafinil)</description>
        </group>
        <group group_id="P3">
          <title>Armodafinil</title>
          <description>Medication (armodafinil) only, without CBTI.&#xD;
Armodafinil: Active medication</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo only, without CBTI.&#xD;
Placebo: Placebo for Nuvigil (armodafinil)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Allocation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ineligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CBT for Insomnia (CBTI) + Armodafinil</title>
          <description>CBT-I with Armodafinil (active medication)&#xD;
Cognitive Behavioral Therapy for Insomnia: Cognitive Behavioral Therapy for Insomnia.&#xD;
Armodafinil: Active medication</description>
        </group>
        <group group_id="B2">
          <title>CBTI + Placebo</title>
          <description>Cognitive Behavioral Therapy for Insomnia with Placebo medication&#xD;
Cognitive Behavioral Therapy for Insomnia: Cognitive Behavioral Therapy for Insomnia.&#xD;
Placebo: Placebo for Nuvigil (armodafinil)</description>
        </group>
        <group group_id="B3">
          <title>Armodafinil</title>
          <description>Medication (armodafinil) only, without CBTI.&#xD;
Armodafinil: Active medication</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo only, without CBTI.&#xD;
Placebo: Placebo for Nuvigil (armodafinil)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.2" spread="9.0"/>
                    <measurement group_id="B2" value="45.0" spread="9.8"/>
                    <measurement group_id="B3" value="48.4" spread="12.4"/>
                    <measurement group_id="B4" value="51.9" spread="7.1"/>
                    <measurement group_id="B5" value="48.2" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change in Sleep Continuity From Baseline to Follow-up, as Measured by the Insomnia Severity Index (ISI).</title>
        <description>This outcome measure is based on changes in sleep continuity, as assessed by the Insomnia Severity Index (ISI), which is administered once at baseline and once at follow-up. The ISI (Morin, 1993) was used to assess perceived sleep difficulties or current insomnia symptom severity (i.e., past two weeks). The ISI is a 7-item, self-report instrument with good reliability and validity, and positively correlated with clinician-rated insomnia diagnoses (Bastien, Vallières, &amp; Morin, 2001). Total scores on the full 7-item scale range from 0 - 28 with higher values representing greater sleep continuity disturbance or insomnia severity.&#xD;
The four different treatment groups will be compared for differences.</description>
        <time_frame>ISI is measured once at baseline and once at follow-up (8-10 weeks apart)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CBT for Insomnia (CBTI) + Armodafinil</title>
            <description>CBT-I with Armodafinil (active medication)&#xD;
Cognitive Behavioral Therapy for Insomnia: Cognitive Behavioral Therapy for Insomnia.&#xD;
Armodafinil: Active medication</description>
          </group>
          <group group_id="O2">
            <title>CBTI + Placebo</title>
            <description>Cognitive Behavioral Therapy for Insomnia with Placebo medication&#xD;
Cognitive Behavioral Therapy for Insomnia: Cognitive Behavioral Therapy for Insomnia.&#xD;
Placebo: Placebo for Nuvigil (armodafinil)</description>
          </group>
          <group group_id="O3">
            <title>Armodafinil</title>
            <description>Medication (armodafinil) only, without CBTI.&#xD;
Armodafinil: Active medication</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo only, without CBTI.&#xD;
Placebo: Placebo for Nuvigil (armodafinil)</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Sleep Continuity From Baseline to Follow-up, as Measured by the Insomnia Severity Index (ISI).</title>
          <description>This outcome measure is based on changes in sleep continuity, as assessed by the Insomnia Severity Index (ISI), which is administered once at baseline and once at follow-up. The ISI (Morin, 1993) was used to assess perceived sleep difficulties or current insomnia symptom severity (i.e., past two weeks). The ISI is a 7-item, self-report instrument with good reliability and validity, and positively correlated with clinician-rated insomnia diagnoses (Bastien, Vallières, &amp; Morin, 2001). Total scores on the full 7-item scale range from 0 - 28 with higher values representing greater sleep continuity disturbance or insomnia severity.&#xD;
The four different treatment groups will be compared for differences.</description>
          <units>units on a scale (ISI)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="2.1"/>
                    <measurement group_id="O2" value="17.9" spread="0.2"/>
                    <measurement group_id="O3" value="7.7" spread="0.5"/>
                    <measurement group_id="O4" value="6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Dropped Out</title>
        <description>Drop-out rates will be calculated by the number of protocol weeks the subject completed before withdrawing from the study. Drop out rates for subjects taking active v. placebo study medication were compared.&#xD;
Withdrawal indicates subjects who were either lost-to-follow-up (LTFU), chose to withdraw (self-withdrawn), were withdrawn by the study's PI (withdrawn by the investigator).</description>
        <time_frame>up to 8 weeks of active study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CBT for Insomnia (CBTI) + Armodafinil</title>
            <description>CBT-I with Armodafinil (active medication)&#xD;
Cognitive Behavioral Therapy for Insomnia: Cognitive Behavioral Therapy for Insomnia.&#xD;
Armodafinil: Active medication</description>
          </group>
          <group group_id="O2">
            <title>CBTI + Placebo</title>
            <description>Cognitive Behavioral Therapy for Insomnia with Placebo medication&#xD;
Cognitive Behavioral Therapy for Insomnia: Cognitive Behavioral Therapy for Insomnia.&#xD;
Placebo: Placebo for Nuvigil (armodafinil)</description>
          </group>
          <group group_id="O3">
            <title>Armodafinil</title>
            <description>Medication (armodafinil) only, without CBTI.&#xD;
Armodafinil: Active medication</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo only, without CBTI.&#xD;
Placebo: Placebo for Nuvigil (armodafinil)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Dropped Out</title>
          <description>Drop-out rates will be calculated by the number of protocol weeks the subject completed before withdrawing from the study. Drop out rates for subjects taking active v. placebo study medication were compared.&#xD;
Withdrawal indicates subjects who were either lost-to-follow-up (LTFU), chose to withdraw (self-withdrawn), were withdrawn by the study's PI (withdrawn by the investigator).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CBT for Insomnia (CBTI) + Armodafinil</title>
          <description>CBT-I with Armodafinil (active medication)&#xD;
Cognitive Behavioral Therapy for Insomnia: Cognitive Behavioral Therapy for Insomnia.&#xD;
Armodafinil: Active medication</description>
        </group>
        <group group_id="E2">
          <title>CBTI + Placebo</title>
          <description>Cognitive Behavioral Therapy for Insomnia with Placebo medication&#xD;
Cognitive Behavioral Therapy for Insomnia: Cognitive Behavioral Therapy for Insomnia.&#xD;
Placebo: Placebo for Nuvigil (armodafinil)</description>
        </group>
        <group group_id="E3">
          <title>Armodafinil</title>
          <description>Medication (armodafinil) only, without CBTI.&#xD;
Armodafinil: Active medication</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo only, without CBTI.&#xD;
Placebo: Placebo for Nuvigil (armodafinil)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Perlis</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>(215) 746-3577</phone>
      <email>mperlis@upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

